We are live on
!
Find out more
Pictet Asset Management Portfolio holdings
AUM
$105B
1-Year Est. Return
38.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+38.07%
3 Year Est. Return
+113.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$90B
AUM Growth
-$2.64B
(-2.9%)
Cap. Flow
+$2.07B
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
17.41%
Holding
2,101
New
60
Increased
1,058
Reduced
623
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$327M |
| 2 |
Broadcom
AVGO
|
+$315M |
| 3 |
Mastercard
MA
|
+$262M |
| 4 |
Intuit
INTU
|
+$226M |
| 5 |
Digital Realty Trust
DLR
|
+$149M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$169M |
| 3 |
WCN
Waste Connections
WCN
|
+$141M |
| 4 |
NextEra Energy
NEE
|
+$134M |
| 5 |
Cadence Design Systems
CDNS
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.36% |
| 2 | Industrials | 16.63% |
| 3 | Healthcare | 13.3% |
| 4 | Financials | 8.12% |
| 5 | Consumer Discretionary | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Sarepta Therapeutics
SRPT
$1.92B
| $60.7M | 0.07% |
937,023
-109,002
| -10% | -$11.5M |
|
277
American Tower
AMT
$79B
| $60.3M | 0.07% |
277,309
+8,327
| +3% | +$1.63M |
|
278
DexCom
DXCM
$33.8B
| $60.1M | 0.07% |
880,659
+218,040
| +33% | +$17.8M |
|
279
Pultegroup
PHM
$25.2B
| $60.1M | 0.07% |
584,739
+10,716
| +2% | +$1.16M |
|
|
SLNO
280
DELISTED
Soleno Therapeutics
SLNO
| $59.9M | 0.07% |
837,836
-14,002
| -2% | -$682K |
|
281
Elevance Health
ELV
$84.7B
| $59.7M | 0.07% |
137,181
-3,125
| -2% | -$1.25M |
|
282
Sysco
SYY
$40.3B
| $59.3M | 0.07% |
789,797
-291,930
| -27% | -$21.4M |
|
283
D.R. Horton
DHI
$42.2B
| $59M | 0.07% |
463,991
+64,349
| +16% | +$8.63M |
|
284
Toronto Dominion Bank
TD
$201B
| $57.7M | 0.06% |
962,440
+12,258
| +1% | +$714K |
|
285
Intel
INTC
$493B
| $57.2M | 0.06% |
2,520,583
-155,133
| -6% | -$3.39M |
|
286
Honeywell
HON
$72.9B
| $56.3M | 0.06% |
282,002
-13,994
| -5% | -$2.83M |
|
287
Stryker
SYK
$134B
| $56M | 0.06% |
150,387
+4,261
| +3% | +$1.62M |
|
288
PayPal
PYPL
$50.5B
| $54.5M | 0.06% |
835,597
+152,901
| +22% | +$11.9M |
|
289
iShares TIPS Bond ETF
TIP
$14.7B
| $54.4M | 0.06% |
491,700
+63,300
| +15% | +$6.88M |
|
|
DAY
290
DELISTED
Dayforce
DAY
| $54.2M | 0.06% |
928,863
+138,737
| +18% | +$8.94M |
|
291
PTC Therapeutics
PTCT
$6.15B
| $54M | 0.06% |
1,042,458
+306,070
| +42% | +$15.3M |
|
292
Ventas
VTR
$44.6B
| $53M | 0.06% |
770,750
-121,950
| -14% | -$7.79M |
|
293
Modine Manufacturing
MOD
$10.5B
| $52.9M | 0.06% |
689,176
+261,489
| +61% | +$25.8M |
|
294
Qiagen
QGEN
$8.81B
| $52.7M | 0.06% |
1,329,454
+499,477
| +60% | +$21M |
|
295
HCA Healthcare
HCA
$89.1B
| $52.4M | 0.06% |
151,679
-8,768
| -5% | -$2.82M |
|
296
Summit Therapeutics
SMMT
$12.1B
| $52.1M | 0.06% |
2,661,604
+1,274,357
| +92% | +$25.6M |
|
297
US Bancorp
USB
$100B
| $52M | 0.06% |
1,230,685
+301,277
| +32% | +$13.9M |
|
298
Ultragenyx Pharmaceutical
RARE
$2.66B
| $52M | 0.06% |
1,409,199
+235,561
| +20% | +$9.8M |
|
299
Moody's
MCO
$82.5B
| $49.8M | 0.06% |
107,030
+4,074
| +4% | +$1.96M |
|
300
Xenon Pharmaceuticals
XENE
$6.11B
| $49.6M | 0.06% |
1,477,617
-18,894
| -1% | -$717K |
|
Similar funds
Pictet Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Pictet Asset Management held 2,101 positions worth $90B, down 2.9% from $92.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Pictet Asset Management's Q1 2025 filing shows 60 new, 1,058 increased, 623 reduced and 92 closed positions. Its largest new stake was Verona Pharma: 703,063 shares worth $44.6M. The largest sale was Intra-Cellular Therapies Inc., an estimated $187M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Industrials and Healthcare.
- Pictet Asset Management's largest Q1 2025 buy was Verona Pharma: 703,063 shares worth $44.6M.
- Pictet Asset Management added most to Synopsys in Q1 2025, an estimated $327M increase.
- Pictet Asset Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $187M.
- Pictet Asset Management fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q1 2025, selling an estimated $46.5M.
- Pictet Asset Management's ten largest holdings make up 17% of its $90B portfolio in Q1 2025.
- Pictet Asset Management opened 60 new positions and closed 92 in Q1 2025.
- Pictet Asset Management's portfolio value fell 2.9% quarter-over-quarter to $90B.
Based on Pictet Asset Management's 13F filing for Q1 2025, filed 5 May 2025.